New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
07:34 EDTRGEN, BMRNRepligen announces asset purchase agreement with BioMarin for HDACi Portfolio
Repligen (RGEN) announced that it has entered into an asset purchase agreement with BioMarin Pharmaceutical (BMRN) to advance Repligen's histone deacetylase inhibitor, or HDACi, portfolio. The HDACi portfolio includes multiple orally bioavailable small molecule compounds as well as enabling technologies. Under the terms of the agreement, Repligen will receive an upfront payment of $2M from BioMarin and it has the potential to receive up to $160M in future milestone payments for the development, regulatory approval and commercial sale of portfolio compounds included in the agreement. In addition, Repligen is eligible to receive royalties on sales of therapeutic products originating from the HDACi portfolio. Potential applications of the HDACi portfolio include Friedreich's ataxia and other neurological disorders.
News For RGEN;BMRN From The Last 14 Days
Check below for free stories on RGEN;BMRN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 11, 2014
15:25 EDTRGENStephens to hold a bus trip
Subscribe for More Information
07:11 EDTRGENRepligen raises FY14 revenue guidance to $59M-$62M from $58M-$61M
Consensus $59M. Total product revenue for 2014 is expected to be $57M-$60M, an increase from previous guidance of $56M-$59M. This reflects annual growth of 20%-26%. Product gross margin for FY14 is expected to be 53%-55%, an increase from our previous guidance of 51%-53%. Total income from operations for FY14 is expected to be $11M-$13M, increased from previous guidance of $10M-$12M. The company expects to end FY14 with $64M-$68M in cash and cash investments, an increase from our previous guidance of $62M-$66M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use